Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

Wednesday, November 30, 2022. Graham has battled excess weight for years, cycling through trendy diets, various drugs, and even bariatric surgery. she started a new medication, Mounjaro ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

In a 2022 study, overweight and obese ... said in a note about the deal Tuesday. The weight-loss market for GLP-1 drugs is relatively new, and not everyone is on board. Read next ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

it has been barred by an old federal law from paying for weight-loss drugs. But last November Biden proposed new rules to allow Medicare and Medicaid to pay for these meds. The change would not ...

21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been ... weight-loss medications more than doubled between 2022 and 2023. Meanwhile, they have also been found to ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...